BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Mivelsiran readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Mivelsiran\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06393712-697@assetmemo.bio
DTSTAMP:20261121T005828Z
DTSTART;VALUE=DATE:20270809
DTEND;VALUE=DATE:20270810
SUMMARY:Mivelsiran: Phase 2 readout est. (NCT06393712)
DESCRIPTION:Mivelsiran\, phase 2.\nStudy: A Phase 2 Trial of ALN-APP in Pat
 ients With Cerebral Amyloid Angiopathy\nEstimated primary completion: 9 Au
 gust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mivelsiran
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT063
 93712
URL:https://assetmemo.bio/drug/mivelsiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05231785-697@assetmemo.bio
DTSTAMP:20261121T005828Z
DTSTART;VALUE=DATE:20290111
DTEND;VALUE=DATE:20290112
SUMMARY:Mivelsiran: Phase 1 readout est. (NCT05231785)
DESCRIPTION:Mivelsiran\, phase 1\, Alzheimer's Disease.\nStudy: A Study to 
 Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD\nEst
 imated primary completion: 11 January 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/mivelsiran#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05231785
URL:https://assetmemo.bio/drug/mivelsiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636811-697@assetmemo.bio
DTSTAMP:20261121T005828Z
DTSTART;VALUE=DATE:20300518
DTEND;VALUE=DATE:20300519
SUMMARY:Mivelsiran: Phase 2 readout est. (NCT07636811)
DESCRIPTION:Mivelsiran\, phase 2\, Alzheimer's Disease.\nStudy: A Study to 
 Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-A
 ssociated Alzheimer's Disease (DS-AD)\nEstimated primary completion: 18 Ma
 y 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/mivelsiran#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076368
 11
URL:https://assetmemo.bio/drug/mivelsiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
